The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 252 participants.

Also called NCT02451293

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 252 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02451293
  • EudraCT 2015-002116-32
Other papers using this trial's data
  • External validity of randomized clinical trial studying preventing depressive symptoms following acute coronary syndrome Brain and behavior, 2021-08 DOI, PubMed 34145796, PMC8413812 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02451293. Randomized; quadruple masking; primary purpose treatment. Start 2016-01-18 (actual); primary completion 2017-08-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
Acronym
MEDACIS
Condition
Depression
Condition
Acute Coronary Syndrome
Intervention (Drug)
Melatonin (N-acetyl-5-methoxytryptamine)
Intervention (Drug)
Placebo
Lead sponsor
Zealand University Hospital (class: other)
Collaborator
Psychiatric Research Unit, Region Zealand, Denmark (class: other)
Collaborator
University of Copenhagen (class: other)
Collaborator
Pharma Nord (class: industry)

Record details

Record id
cardio:ct-nct02451293
Content hash
6c863bfa244b1346d4663cd15ac90995b4bf70a58533e4d4c68a9b210078f463